Patents by Inventor Jacques Dikansky
Jacques Dikansky has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 10092613Abstract: A method of controlling body weight in humans by administering an amount of decaffeinated green coffee extract effective to treat a subject. A preferred green coffee extract contains a ratio of 4-caffeoylquinic acid (4-CQA) to total chlorogenic acids (tCGA) (5-CQA/tCGA) of from about 0.1 to about 0.2. More preferably, the green coffee extract comprises from about 6% to about 8% of 4-caffeoylquinic acid and has a total chlorogenic acid concentration that exceeds about 45%. A preferred method of administration consists of administering the green coffee extracts is a dosage of about 200 mg twice a day prior to meals on an empty stomach.Type: GrantFiled: June 6, 2016Date of Patent: October 9, 2018Assignee: NATUREX, S.A.Inventors: Alvin Ibarra, Marc Roller, Jacques Dikansky
-
Patent number: 9956241Abstract: Disclosed are methods of enhancing neurocognitive function by administering of American Ginseng. Preferred dosages in the range of 5 to 50 mg total ginsenosides enhance cognitive function—including, improvement of working memory (WM) performance, attentional performance (e.g., Choice Reaction Time accuracy), and calmness.Type: GrantFiled: February 27, 2015Date of Patent: May 1, 2018Assignee: Naturex, S.A.Inventors: Andrew Scholey, Alvin Ibarra, Kan He, Marc Roller, Jacques Dikansky
-
Publication number: 20160287655Abstract: A method of controlling body weight in humans by administering an amount of decaffeinated green coffee extract effective to treat a subject. A preferred green coffee extract contains a ratio of 4-caffeoylquinic acid (4-CQA) to total chlorogenic acids (tCGA) (5-CQA/tCGA) of from about 0.1 to about 0.2. More preferably, the green coffee extract comprises from about 6% to about 8% of 4-caffeoylquinic acid and has a total chlorogenic acid concentration that exceeds about 45%. A preferred method of administration consists of administering the green coffee extracts is a dosage of about 200 mg twice a day prior to meals on an empty stomach.Type: ApplicationFiled: June 6, 2016Publication date: October 6, 2016Applicant: NATUREX, S.A.Inventors: Alvin IBARRA, Marc ROLLER, Jacques DIKANSKY
-
Patent number: 9358264Abstract: A method of controlling body weight in humans by administering an amount of decaffeinated green coffee extract effective to treat a subject. A preferred green coffee extract contains a ratio of 4-caffeoylquinic acid (4-CQA) to total chlorogenic acids (tCGA) (5-CQA/tCGA) of from about 0.1 to about 0.2. More preferably, the green coffee extract comprises from about 6% to about 8% of 4-caffeoylquinic acid and has a total chlorogenic acid concentration that exceeds about 45%. A preferred method of administration consists of administering the green coffee extracts is a dosage of about 200 mg twice a day prior to meals on an empty stomach.Type: GrantFiled: March 25, 2011Date of Patent: June 7, 2016Assignee: NATUREX, S.A.Inventors: Alvin Ibarra, Marc Roller, Jacques DiKansky
-
Publication number: 20160015766Abstract: A method of controlling body weight in humans by administering an amount of decaffeinated green coffee extract effective to treat a subject. A preferred green coffee extract contains a ratio of 4-caffeoylquinic acid (4-CQA) to total chlorogenic acids (tCGA) (5-CQA/tCGA) of from about 0.1 to about 0.2. More preferably, the green coffee extract comprises from about 6% to about 8% of 4-caffeoylquinic acid and has a total chlorogenic acid concentration that exceeds about 45%. A preferred method of administration consists of administering the green coffee extracts is a dosage of about 200 mg twice a day prior to meals on an empty stomach.Type: ApplicationFiled: March 25, 2011Publication date: January 21, 2016Applicant: NATUREX, S.A.Inventors: Alvin IBARRA, Marc ROLLER, Jacques DIKANSKY
-
Publication number: 20150306119Abstract: Disclosed are methods of enhancing neurocognitive function by administering of American Ginseng. Preferred dosages in the range of 5 to 50 mg total ginsenosides enhance cognitive function—including, improvement of working memory (WM) performance, attentional performance (e.g., Choice Reaction Time accuracy), and calmness.Type: ApplicationFiled: February 27, 2015Publication date: October 29, 2015Applicant: NATUREX, S.A.Inventors: Andrew SCHOLEY, Alvin IBARRA, Kan HE, Marc ROLLER, Jacques DIKANSKY
-
Patent number: 9011936Abstract: Disclosed are methods of alleviating oxidative stress, regulating blood glucose levels, and controlling pancreatic lipase activity by administering a Rosemary extract. Such methods may be useful to help body weight and body fat, prevent obesity, and treat hyperglycemia, hyperinsulinemia, cardiovascular disease and Type-2 diabetes. Preferred extracts contain 20% or 50% carnosic acid.Type: GrantFiled: October 16, 2009Date of Patent: April 21, 2015Assignee: Naturex, S.A.Inventors: Kan He, Marc Roller, Alvin Ibarra, Naisheng Bai, Jacques DiKansky
-
Patent number: 8980342Abstract: A method of enhancing physical performance during exercise by administering an amount of a grape extract effective to treat a subject. A preferred grape extract comprises a concentration of flavanol monomers of greater than about 5% by weight, and more preferably within a range from about 12% by weight to about 50% by weight, and a concentration of flavanol dimers preferably greater than about 2% by weight, and more preferably within a range from about 6% by weight to about 20% by weight. The flavanol monomers preferably include catechin, epicatechin, epicatechin gallate, and gallic acid. The flavanol dimers preferably include procyanidin B1, procyanidin B2, procyanidin B3, procyanidin B4, and procyanidin B2-O-gallate.Type: GrantFiled: August 20, 2008Date of Patent: March 17, 2015Assignee: Naturex, S.A.Inventors: Benoit Lemaire, Sophie Lafay, Alvin Ibarra, Marc Roller, Jacques DiKansky
-
Publication number: 20150072042Abstract: A method of controlling body weight in humans by administering an amount of decaffeinated green coffee extract effective to treat a subject. A preferred green coffee extract contains a ratio of 4-caffeoylquinic acid (4-CQA) to total chlorogenic acids (tCGA) (5-CQA/tCGA) of from about 0.1 to about 0.2. More preferably, the green coffee extract comprises from about 6% to about 8% of 4-caffeoylquinic acid and has a total chlorogenic acid concentration that exceeds about 45%. A preferred method of administration consists of administering the green coffee extracts is a dosage of about 200 mg twice a day prior to meals on an empty stomach.Type: ApplicationFiled: March 25, 2011Publication date: March 12, 2015Applicant: NATUREX, S.A.Inventors: Alvin IBARRA, Marc ROLLER, Jacques DiKANSKY
-
Patent number: 8968800Abstract: Disclosed are methods of enhancing neurocognitive function by administering of American Ginseng. Preferred dosages in the range of 5 to 50 mg total genosides enhance cognitive function—including, improvement of working memory (WM) performance, attentional performance (e.g., Choice Reaction Time accuracy), and calmness.Type: GrantFiled: November 3, 2011Date of Patent: March 3, 2015Assignee: Naturex, S.A.Inventors: Andrew Scholey, Alvin Ibarra, Kan He, Marc Roller, Jacques Dikansky
-
Patent number: 8293292Abstract: A Fraxinus excelsior seed extract that can be administered for therapeutic treatment of a subject, including a human, by blocking fat synthesis, activating PPAR-alpha, increasing hypoglycemic activity, reducing bodyweight, controlling fasting plasma insulin levels against hyperinsulinemia, and promoting insulin sensitivity and causing a beneficial acute insulinotropic effect. The Fraxinus excelsior seed extract includes, inter alia, an isolated compound (2S,3E,4S)2H-Pyran-4-acetic acid-3-ethylidene-2-[(6-O-?-D-glucopyranosyl-?-D-glucopyranosyl)oxy]-3,4-dihydro-5-(methoxycarbonyl)methyl ester, commonly called excelside A, an isolated compound (2S,3E,4S) 2H-Pyran-4-acetic acid-3-ethylidene-2-[(6-O-?-D-glucopyranosyl-?-D-glucopyranosyl)oxy]-3,4-dihydro-5-(methoxycarbonyl)2-(4-hydroxyphenyl)ethyl ester, commonly called excelside B, and the compounds GI5, GI3, nuzhenide, and oleoside dimethyl ester.Type: GrantFiled: November 10, 2011Date of Patent: October 23, 2012Assignee: Naturex, S.A.Inventors: Kan He, Marc Roller, Antoine Bily, Naisheng Bai, Jacques DiKansky, Alvin Ibarra
-
Patent number: 8142826Abstract: A Fraxinus excelsior seed extract that can be administered for therapeutic treatment of a subject, including a human, by blocking fat synthesis, activating PPAR-alpha, increasing hypoglycemic activity, reducing bodyweight, controlling fasting plasma insulin levels against hyperinsulinemia, and promoting insulin sensitivity and causing a beneficial acute insulinotropic effect. The Fraxinus excelsior seed extract includes, inter alia, an isolated compound (2S,3E,4S) 2H-Pyran-4-acetic acid-3-ethylidene-2-[(6-O-?-D-glucopyranosyl-?-D-glucopyranosyl) oxy]-3,4-dihydro-5-(methoxycarbonyl)methyl ester, commonly called excelside A, an isolated compound (2S,3E,4S) 2H-Pyran-4-acetic acid-3-ethylidene-2-[(6-O-?-D-glucopyranosyl-?-D-glucopyranosyl)oxy]-3,4-dihydro-5-(methoxycarbonyl) 2-(4-hydroxyphenyl)ethyl ester, commonly called excelside B, and the compounds GI5, GI3, nuzhenide, and oleoside dimethyl ester.Type: GrantFiled: August 4, 2008Date of Patent: March 27, 2012Assignee: Naturex, Inc.Inventors: Kan He, Marc Roller, Antoine Bily, Naisheng Bai, Jacques Dikansky, Alvin Ibarra
-
Publication number: 20120058210Abstract: A Fraxinus excelsior seed extract that can be administered for therapeutic treatment of a subject, including a human, by blocking fat synthesis, activating PPAR-alpha, increasing hypoglycemic activity, reducing bodyweight, controlling fasting plasma insulin levels against hyperinsulinemia, and promoting insulin sensitivity and causing a beneficial acute insulinotropic effect. The Fraxinus excelsior seed extract includes, inter alia, an isolated compound (2S,3E,4S) 2H-Pyran-4-acetic acid-3-ethylidene-2-[(6-O-?-D-glucopyranosyl-?-D-glucopyranosyl)oxy]-3,4-dihydro-5-(methoxycarbonyl)methyl ester, commonly called excelside A, an isolated compound (2S,3E,4S) 2H-Pyran-4-acetic acid-3-ethylidene-2-[(6-O-?-D-glucopyranosyl-?-D-glucopyranosyl)oxy]-3,4-dihydro-5-(methoxycarbonyl) 2-(4-hydroxyphenyl)ethyl ester, commonly called excelside B, and the compounds GI5, GI3, nuzhenide, and oleoside dimethyl ester.Type: ApplicationFiled: November 10, 2011Publication date: March 8, 2012Inventors: KAN HE, Marc ROLLER, Antoine BILY, Naisheng BAI, Jacques DIKANSKY, Alvin IBARRA
-
Publication number: 20120046239Abstract: Disclosed are methods of enhancing neurocognitive function by administering of American Ginseng. Preferred dosages in the range of 5 to 50 mg total genosides enhance cognitive function—including, improvement of working memory (WM) performance, attentional performance (e.g., Choice Reaction Time accuracy), and calmness.Type: ApplicationFiled: November 3, 2011Publication date: February 23, 2012Inventors: Andrew Scholey, Alvin Ibarra, Kan He, Marc Roller, Jacques Dikansky
-
Publication number: 20110223281Abstract: A method of controlling body weight in humans by administering an amount of decaffeinated green coffee extract effective to treat a subject. A preferred green coffee extract contains a ratio of 4-caffeoylquinic acid (4-CQA) to total chlorogenic acids (tCGA) (5-CQA/tCGA) of from about 0.1 to about 0.2. More preferably, the green coffee extract comprises from about 6% to about 8% of 4-caffeoylquinic acid and has a total chlorgenic acid concentration that exceeds about 45%. A preferred method of administration consists of administering the green coffee extracts is a dosage of about 200 mg twice a day prior to meals on an empty stomach.Type: ApplicationFiled: March 25, 2011Publication date: September 15, 2011Inventors: Alvin IBARRA, Marc ROLLER, Jacques DiKANSKY
-
Publication number: 20110091580Abstract: Disclosed are methods of alleviating oxidative stress, regulating blood glucose levels, and controlling pancreatic lipase activity by administering a Rosemary extract. Such methods may be useful to help body weight and body fat, prevent obesity, and treat hyperglycemia, hyperinsulinemia, cardiovascular disease and Type-2 diabetes. Preferred extracts contain 20% or 50% carnosic acid.Type: ApplicationFiled: October 16, 2009Publication date: April 21, 2011Inventors: KAN HE, Marc Roller, Alvin Ibarra, Naisheng Bai, Jacques Dikansky
-
Publication number: 20100278944Abstract: Disclosed are methods of enhancing neurocognitive function by administering of American Ginseng. Preferred dosages in the range of 5 to 50 mg total genosides enhance cognitive function—including, improvement of working memory (WM) performance, attentional performance (e.g., Choice Reaction Time accuracy), and calmness.Type: ApplicationFiled: May 4, 2009Publication date: November 4, 2010Inventors: Andrew Scholey, Alvin Ibarra, Kan He, Marc Roller, Jacques Dikansky
-
Publication number: 20100112098Abstract: A method of controlling body weight in humans by administering an amount of decaffeinated green coffee extract effective to treat a subject. A preferred green coffee extract contains a ratio of 5-caffeoylquinic acid (5-CQA) and total chlorogenic acids (tCGA) (5-CQA/tCGA) of between about 0.2 and 0.3. More preferably, the concentration of tCGA is greater than about 45% and the concentration of 5-CQA is less than about 10%. A preferred method of administration consists of administering between about 200 mg and about 1,000 mg per day, more preferably administering about 400 mg per day.Type: ApplicationFiled: October 31, 2008Publication date: May 6, 2010Inventors: Benoit Lemaire, Sophie Lafay, Karine Nardon, Alvin Ibarra, Marc Roller, Jacques Dikansky
-
Publication number: 20100047372Abstract: A method of enhancing physical performance during exercise by administering an amount of a grape extract effective to treat a subject. A preferred grape extract comprises a concentration of flavanol monomers of greater than about 5% by weight, and more preferably within a range from about 12% by weight to about 50% by weight, and a concentration of flavanol dimers preferably greater than about 2% by weight, and more preferably within a range from about 6% by weight to about 20% by weight. The flavanol monomers preferably include catechin, epicatechin, epicatechin gallate, and gallic acid. The flavanol dimers preferably include procyanidin B1, procyanidin B2, procyanidin B3, procyanidin B4, and procyanidin B2-O-gallate.Type: ApplicationFiled: August 20, 2008Publication date: February 25, 2010Inventors: Benoit LEMAIRE, Sophie Lafay, Alvin Ibarra, Marc Roller, Jacques Dikansky
-
Publication number: 20090117214Abstract: A Fraxinus excelsior seed extract that can be administered for therapeutic treatment of a subject, including a human, by blocking fat synthesis, activating PPAR-alpha, increasing hypoglycemic activity, reducing bodyweight, controlling fasting plasma insulin levels against hyperinsulinemia, and promoting insulin sensitivity and causing a beneficial acute insulinotropic effect. The Fraxinus excelsior seed extract includes, inter alia, an isolated compound (2S,3E,4S) 2H-Pyran-4-acetic acid-3-ethylidene-2-[(6-O-?-D-glucopyranosyl-?-D-glucopyranosyl) oxy]-3,4-dihydro-5-(methoxycarbonyl)methyl ester, commonly called excelside A, an isolated compound (2S,3E,4S) 2H-Pyran-4-acetic acid-3-ethylidene-2-[(6-O-?-D-glucopyranosyl-?-D-glucopyranosyl)oxy]-3,4-dihydro-5-(methoxycarbonyl) 2-(4-hydroxyphenyl)ethyl ester, commonly called excelside B, and the compounds G15, G13, nuzhenide, and oleoside dimethyl ester.Type: ApplicationFiled: August 4, 2008Publication date: May 7, 2009Inventors: Kan He, Marc Roller, Antonie Bily, Naisheng Bai, Jacques Dikansky, Alvin Ibarra